Skip to content

Effect of lactose-free milk powder on symptoms of lactose intolerance in healthy adults

Effect of lactose-free milk powder on symptoms of lactose intolerance in healthy adults

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400085706
Enrollment
Unknown
Registered
2024-06-17
Start date
2024-06-25
Completion date
Unknown
Last updated
2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lactose intolerance

Interventions

Group A:50g of lactose-free milk powder was mixed into 300ml solution for the subjects to drink for 14 days
Group B:50g of lactose-free milk powder was mixed into 300ml solution for the subjects to drink for 28 days

Sponsors

West China Fourth Hospital/West China School of Public Health, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 49 Years

Inclusion criteria

Inclusion criteria: 18~49 years old; 18.5=BMI=27.9kg/?; Adults with a diagnosis of lactose intolerance or lactose malabsorption; Volunteers who voluntarily participate in the trial in its entirety and sign the informed consent form

Exclusion criteria

Exclusion criteria: Pregnant, within 6 months of childbirth and lactating women; Those with other acute or chronic diseases or allergies; Volunteers who are taking drugs or nutritional preparations that may affect the results of the trial, such as antibiotics and intestinal probiotics, as well as related clinical treatments that may affect the results of the trial; Volunteers with irregular diet, work and rest, or special dietary habits and living habits, such as alcoholism, smoking, liking sugary drinks (>1000ml/day), changes in dietary patterns within two months, and food restrictions; Volunteers who are currently participating in other interventional studies or observational studies; Those who have an overgrowth of small intestinal bacteria

Design outcomes

Primary

MeasureTime frame
Hydrogen concentration;Intestinal bifidobacteria content;Intestinal short-chain fatty acid content;

Countries

China

Contacts

Public ContactLi Ming

West China Fourth Hospital/West China School of Public Health, Sichuan University

1dmancheng@163.com+86 130 9639 7110

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026